The Embold trial continues unchanged, but investors have got cold feet.
The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
Long-awaited gamma-delta Car-T data sees the response rate fall to 20% at six months, but when is a relapse not a relapse?
Arcellx, Gracell and Oricell work hard to prove that there is still space for new Car-T therapies in multiple myeloma.
The company believes its new combination technology can make insulin injections a thing of the past.
Lower – and shorter – efficacy add to serious doubts about the TIL therapy's future.